Long-Term Outcomes of Balloon TACE for HCC: An European Multicentre Single-Arm Retrospective Study.

Pierleone LucatelliBianca RoccoThierry De BeareGontran VersetFabio FucilliElio DamatoAlexandro PaccapeloLorenzo BraccischiMakoto Taninokuchi TomassoniAna-Maria BucalauCarlo CatalanoCristina Mosconi

Published in: Cardiovascular and interventional radiology (2024)

bTACE demonstrated high efficacy for HCC, with a complete response in 58.9% of patients, a median local recurrence-free survival of 31.0 months and a mean overall survival of 50.0 months.

Keyphrases

free survival
end stage renal disease
ejection fraction
newly diagnosed
clinical trial
patient reported outcomes
cross sectional
double blind